Repeated regression of pulmonary metastases from renal cell carcinoma after treatment using different interferon-alpha preparations

Mototsugu Oya, Hirotaka Asakura, Ryuichi Mizuno, Ken Marumo, Masaru Murai

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A 49-year-old man with pulmonary metastasis from renal cell carcinoma (RCC) was treated with recombinant IFN-α2b (Intron A®). A complete response was achieved within 4 months and thereafter persisted for 5 years until he developed another lung lesion. Interleukin-2 (Imunace®) was administered without any response. Finally, lie was treated by natural IFN-α (OIF®). The pulmonary lesion achieved a partial response after 11 months of treatment. Because IFN-α preparations include different subtypes, changing the use of IFN-α preparations may thus be a potentially useful option for the successful immunotherapy of RCC.

Original languageEnglish
Pages (from-to)135-137
Number of pages3
JournalBiomedical Research
Volume26
Issue number3
DOIs
Publication statusPublished - 2005 Jun

Fingerprint

Renal Cell Carcinoma
Interferon-alpha
Introns
Interleukin-2
Cells
Neoplasm Metastasis
Lung
Immunotherapy
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Repeated regression of pulmonary metastases from renal cell carcinoma after treatment using different interferon-alpha preparations. / Oya, Mototsugu; Asakura, Hirotaka; Mizuno, Ryuichi; Marumo, Ken; Murai, Masaru.

In: Biomedical Research, Vol. 26, No. 3, 06.2005, p. 135-137.

Research output: Contribution to journalArticle

@article{19a54c77394b4751b5d1b68359d142d8,
title = "Repeated regression of pulmonary metastases from renal cell carcinoma after treatment using different interferon-alpha preparations",
abstract = "A 49-year-old man with pulmonary metastasis from renal cell carcinoma (RCC) was treated with recombinant IFN-α2b (Intron A{\circledR}). A complete response was achieved within 4 months and thereafter persisted for 5 years until he developed another lung lesion. Interleukin-2 (Imunace{\circledR}) was administered without any response. Finally, lie was treated by natural IFN-α (OIF{\circledR}). The pulmonary lesion achieved a partial response after 11 months of treatment. Because IFN-α preparations include different subtypes, changing the use of IFN-α preparations may thus be a potentially useful option for the successful immunotherapy of RCC.",
author = "Mototsugu Oya and Hirotaka Asakura and Ryuichi Mizuno and Ken Marumo and Masaru Murai",
year = "2005",
month = "6",
doi = "10.2220/biomedres.26.135",
language = "English",
volume = "26",
pages = "135--137",
journal = "Biomedical Research (Japan)",
issn = "0388-6107",
publisher = "Biomedical Research Foundation",
number = "3",

}

TY - JOUR

T1 - Repeated regression of pulmonary metastases from renal cell carcinoma after treatment using different interferon-alpha preparations

AU - Oya, Mototsugu

AU - Asakura, Hirotaka

AU - Mizuno, Ryuichi

AU - Marumo, Ken

AU - Murai, Masaru

PY - 2005/6

Y1 - 2005/6

N2 - A 49-year-old man with pulmonary metastasis from renal cell carcinoma (RCC) was treated with recombinant IFN-α2b (Intron A®). A complete response was achieved within 4 months and thereafter persisted for 5 years until he developed another lung lesion. Interleukin-2 (Imunace®) was administered without any response. Finally, lie was treated by natural IFN-α (OIF®). The pulmonary lesion achieved a partial response after 11 months of treatment. Because IFN-α preparations include different subtypes, changing the use of IFN-α preparations may thus be a potentially useful option for the successful immunotherapy of RCC.

AB - A 49-year-old man with pulmonary metastasis from renal cell carcinoma (RCC) was treated with recombinant IFN-α2b (Intron A®). A complete response was achieved within 4 months and thereafter persisted for 5 years until he developed another lung lesion. Interleukin-2 (Imunace®) was administered without any response. Finally, lie was treated by natural IFN-α (OIF®). The pulmonary lesion achieved a partial response after 11 months of treatment. Because IFN-α preparations include different subtypes, changing the use of IFN-α preparations may thus be a potentially useful option for the successful immunotherapy of RCC.

UR - http://www.scopus.com/inward/record.url?scp=27244461045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27244461045&partnerID=8YFLogxK

U2 - 10.2220/biomedres.26.135

DO - 10.2220/biomedres.26.135

M3 - Article

VL - 26

SP - 135

EP - 137

JO - Biomedical Research (Japan)

JF - Biomedical Research (Japan)

SN - 0388-6107

IS - 3

ER -